Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30224629)

  • 1. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
    Wagner AH; Devarakonda S; Skidmore ZL; Krysiak K; Ramu A; Trani L; Kunisaki J; Masood A; Waqar SN; Spies NC; Morgensztern D; Waligorski J; Ponce J; Fulton RS; Maggi LB; Weber JD; Watson MA; O'Conor CJ; Ritter JH; Olsen RR; Cheng H; Mukhopadhyay A; Can I; Cessna MH; Oliver TG; Mardis ER; Wilson RK; Griffith M; Griffith OL; Govindan R
    Nat Commun; 2018 Sep; 9(1):3787. PubMed ID: 30224629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy.
    Wang Q; Zeng F; Sun Y; Qiu Q; Zhang J; Huang W; Huang J; Huang X; Guo L
    Clin Cancer Res; 2018 Feb; 24(4):950-962. PubMed ID: 29208667
    [No Abstract]   [Full Text] [Related]  

  • 6. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
    Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
    Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
    Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
    Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
    Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
    Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer.
    Kohmo S; Kijima T; Otani Y; Mori M; Minami T; Takahashi R; Nagatomo I; Takeda Y; Kida H; Goya S; Yoshida M; Kumagai T; Tachibana I; Yokota S; Kawase I
    Cancer Res; 2010 Oct; 70(20):8025-35. PubMed ID: 20940407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
    Donakonda S; Sinha S; Dighe SN; Rao MRS
    Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
    Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
    Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
    Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
    Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.
    Ye M; Wei T; Wang Q; Sun Y; Tang R; Guo L; Zhu W
    Biochem Biophys Res Commun; 2017 Apr; 486(2):349-356. PubMed ID: 28302484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular Vesicles Derived circSH3PXD2A Inhibits Chemoresistance of Small Cell Lung Cancer by miR-375-3p/YAP1.
    Chao F; Zhang Y; Lv L; Wei Y; Dou X; Chang N; Yi Q; Li M
    Int J Nanomedicine; 2023; 18():2989-3006. PubMed ID: 37304971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.